PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21615395-7	2011	Treatment of myotubes with a selective high-affinity PPARdelta agonist (GW501516) did not change mean PPARD, but enhanced mean PDK4 and ANGPTL4 expression 13- and 16-fold, respectively (P < 0 0001, both).	GW 501516	72-80	pyruvate dehydrogenase kinase 4	Homo sapiens	127-131	
17500064-8	2007	Concomitant with these metabolic changes, we provide evidence that GW501516 increases the expression of key genes involved in lipid metabolism (FABP3, CPT1, and PDK4) by a PPARdelta-dependent mechanism.	GW 501516	67-75	pyruvate dehydrogenase kinase 4	Homo sapiens	161-165	
21615395-8	2011	The individual PDK4 and ANGPTL4 expression levels reached upon GW501516 treatment were associated with donors" insulin sensitivity neither (P > 0 2, both).	GW 501516	63-71	pyruvate dehydrogenase kinase 4	Homo sapiens	15-19	
21615395-9	2011	However, GW501516-mediated fold increments in PDK4 and ANGPTL4 expression, reflecting PPARdelta responsiveness, were positively associated with donors" insulin sensitivity derived from OGTT (P = 0 0182 and P = 0 0231, respectively) and hyperinsulinemic-euglycemic clamp (P = 0 0046 and P = 0 0258, respectively).	GW 501516	9-17	pyruvate dehydrogenase kinase 4	Homo sapiens	46-50